Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: BioNTech 0.114, CSL 3.6525.
* CSL reports semi-annually. Values are evenly split across both quarters within each half.
BioNTech vs CSL Net Worth and Market Cap
BioNTech (BNTX) and CSL (CSL.AX) are peers in Vaccines. BioNTech reported revenue of $114M as of Q2 2026, compared with $7.3B for CSL. CSL leads on revenue.
BioNTech's gross margin is 8.1% versus 44.4% for CSL. BioNTech's net margin is -777.3% versus -40.2% for CSL.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: CSL +0.7%, BioNTech -59.6%.
- CSL made an operating profit in its latest quarter (19.0% margin); BioNTech made an operating loss (-897.8%).
- BioNTech's KPIs on Sterling include Cash, Cash Equivalents, and Security Investments (Quarterly) and COMIRNATY Doses as Printed.
- CSL's KPIs on Sterling include Behring Revenue by Therapy (Annual) and Behring IVIG vs SCIG Revenue (Annual).
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, BioNTech, CSL.| Metric | BioNTech | CSL |
|---|---|---|
| Market Cap | - | - |
| Revenue | $114.00M | $7.30B |
| Cost of Revenue | $105.00M | $4.06B |
| Gross Profit | $9.00M | $3.24B |
| Operating Income | $-1.02B | $1.39B |
| Net Income | $-886.00M | $-2.94B |
| R&D Expense | $595.00M | $614.00M |
| Earnings Per Share | -$3.5 | -$6.14 |
| Gross Margin | 8.1% | 44.4% |
| Operating Margin | -897.8% | 19.0% |
| Net Profit Margin | -777.3% | -40.2% |
| Free Cash Flow | $-48.00M | $1.76B |
| Cumulative Free Cash Flow | $19.56B | $21.56B |
| Operating Cash Flow | $12.00M | $2.09B |
| Cash & Equivalents | $10.52B | $1.51B |